Barclays PLC raised its stake in Anavex Life Sciences Corp. (NASDAQ:AVXL – Get Rating) by 1,792.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 189,290 shares of the biotechnology company's stock after acquiring an additional 179,290 shares during the period. Barclays PLC owned 0.24% of Anavex Life Sciences worth $1,953,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of AVXL. Lazard Asset Management LLC acquired a new position in Anavex Life Sciences in the second quarter valued at $26,000. SeaCrest Wealth Management LLC acquired a new position in Anavex Life Sciences in the second quarter valued at $44,000. Quantbot Technologies LP acquired a new position in Anavex Life Sciences in the second quarter valued at $64,000. Janney Montgomery Scott LLC acquired a new position in Anavex Life Sciences in the third quarter valued at $108,000. Finally, Atria Wealth Solutions Inc. acquired a new stake in shares of Anavex Life Sciences during the first quarter worth about $136,000. Institutional investors and hedge funds own 31.22% of the company's stock.

Anavex Life Sciences Stock Down 1.0 %

Shares of NASDAQ:AVXL opened at $11.26 on Friday. The company has a market cap of $878.62 million, a P/E ratio of -18.16 and a beta of 0.77. Anavex Life Sciences Corp. has a 52 week low of $7.13 and a 52 week high of $15.24. The company has a 50-day moving average price of $9.60 and a 200 day moving average price of $10.46.

Analysts Set New Price Targets

Several brokerages have recently weighed in on AVXL. StockNews.com began coverage on shares of Anavex Life Sciences in a research note on Wednesday, October 12th. They set a "sell" rating for the company. Jonestrading increased their target price on shares of Anavex Life Sciences from $40.00 to $80.00 in a research note on Friday, December 2nd. HC Wainwright increased their target price on shares of Anavex Life Sciences from $42.00 to $50.00 and gave the stock a "buy" rating in a research note on Tuesday, January 3rd. Finally, Cantor Fitzgerald downgraded shares of Anavex Life Sciences from an "overweight" rating to a "neutral" rating and decreased their target price for the stock from $16.00 to $11.00 in a research note on Tuesday, December 6th.

About Anavex Life Sciences

(Get Rating)

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome.

Further Reading

• Get a free copy of the StockNews.com research report on Anavex Life Sciences (AVXL)
• Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
• Zimmer Biomet Beats on Earnings, Growth May be Priced In
• AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
• Ford Stock Going Forward After Big Earnings Flop
• Insiders And Institutions Buy Wolverine Worldwide

Want to see what other hedge funds are holding AVXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anavex Life Sciences Corp. (NASDAQ:AVXL – Get Rating).

Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.